| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | fructose transmembrane transporter activity | 3.58e-05 | 9 | 153 | 3 | GO:0005353 | |
| GeneOntologyMolecularFunction | hexose transmembrane transporter activity | 3.70e-05 | 25 | 153 | 4 | GO:0015149 | |
| GeneOntologyMolecularFunction | D-glucose transmembrane transporter activity | 3.70e-05 | 25 | 153 | 4 | GO:0055056 | |
| GeneOntologyMolecularFunction | monosaccharide transmembrane transporter activity | 5.07e-05 | 27 | 153 | 4 | GO:0015145 | |
| GeneOntologyMolecularFunction | inward rectifier potassium channel activity | 5.88e-05 | 28 | 153 | 4 | GO:0005242 | |
| GeneOntologyMolecularFunction | calcium ion binding | FKBP10 FAT4 PCDHGB5 FAT3 PCDHB7 CDH23 ADGRV1 PPEF2 DNAH7 THBS1 NELL2 THBS2 EYS THBS4 SULF2 PCDHGA12 GCA | 6.33e-05 | 749 | 153 | 17 | GO:0005509 |
| GeneOntologyMolecularFunction | sugar transmembrane transporter activity | 6.78e-05 | 29 | 153 | 4 | GO:0051119 | |
| GeneOntologyMolecularFunction | N-acetylglucosamine-6-sulfatase activity | 1.74e-04 | 3 | 153 | 2 | GO:0008449 | |
| GeneOntologyMolecularFunction | glycosaminoglycan binding | 2.29e-04 | 268 | 153 | 9 | GO:0005539 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | SLC24A5 SLC2A7 SLC25A33 CFTR SLC38A5 ABCC9 SLC6A15 SLC2A2 SLC2A4 SLC2A5 SLC6A3 KCNH6 SIDT2 SLC15A2 KCND1 KCNH2 KCNJ10 SCN3A SLC22A20P SLC29A4 SLC27A4 | 2.67e-04 | 1180 | 153 | 21 | GO:0022857 |
| GeneOntologyMolecularFunction | carbohydrate transmembrane transporter activity | 2.96e-04 | 42 | 153 | 4 | GO:0015144 | |
| GeneOntologyMolecularFunction | transporter activity | SLC24A5 SLC2A7 SLC25A33 CFTR SLC38A5 ABCC9 SLC6A15 SLC2A2 SLC2A4 SLC2A5 SLC6A3 KCNH6 SIDT2 SLC15A2 KCND1 KCNH2 KCNJ10 SCN3A NPC1L1 SLC22A20P SLC29A4 SLC27A4 | 3.38e-04 | 1289 | 153 | 22 | GO:0005215 |
| GeneOntologyMolecularFunction | neurotransmitter transmembrane transporter activity | 5.30e-04 | 21 | 153 | 3 | GO:0005326 | |
| GeneOntologyMolecularFunction | extracellular matrix structural constituent | 6.26e-04 | 188 | 153 | 7 | GO:0005201 | |
| GeneOntologyMolecularFunction | ATP-activated inward rectifier potassium channel activity | 8.57e-04 | 6 | 153 | 2 | GO:0015272 | |
| GeneOntologyMolecularFunction | mitogen-activated protein kinase kinase kinase binding | 1.01e-03 | 26 | 153 | 3 | GO:0031435 | |
| GeneOntologyMolecularFunction | voltage-gated potassium channel activity | 1.13e-03 | 102 | 153 | 5 | GO:0005249 | |
| GeneOntologyBiologicalProcess | fructose transmembrane transport | 4.62e-05 | 10 | 153 | 3 | GO:0015755 | |
| GeneOntologyBiologicalProcess | transport across blood-brain barrier | 4.65e-05 | 87 | 153 | 6 | GO:0150104 | |
| GeneOntologyBiologicalProcess | vascular transport | 4.96e-05 | 88 | 153 | 6 | GO:0010232 | |
| GeneOntologyCellularComponent | apical part of cell | FAT4 SLC2A7 CFTR DVL2 ITGA8 CDH23 LCT SLC2A2 SLC2A5 SLC15A2 DSTYK KCNJ10 NPC1L1 CPO CTSB MUC4 SLC29A4 | 2.01e-06 | 592 | 155 | 17 | GO:0045177 |
| GeneOntologyCellularComponent | apical plasma membrane | SLC2A7 CFTR LCT SLC2A2 SLC2A5 SLC15A2 DSTYK KCNJ10 NPC1L1 CPO CTSB MUC4 SLC29A4 | 7.18e-05 | 487 | 155 | 13 | GO:0016324 |
| GeneOntologyCellularComponent | TEAD-YAP complex | 1.63e-04 | 3 | 155 | 2 | GO:0140552 | |
| GeneOntologyCellularComponent | monoatomic ion channel complex | CATSPERE CATSPERD CFTR ABCC9 SACM1L KCNH6 KCND1 KCNH2 KCNJ10 SCN3A | 5.34e-04 | 378 | 155 | 10 | GO:0034702 |
| GeneOntologyCellularComponent | transmembrane transporter complex | CATSPERE CATSPERD CFTR ABCC9 SACM1L WDR93 KCNH6 KCND1 KCNH2 KCNJ10 SCN3A UQCRC2 | 5.41e-04 | 523 | 155 | 12 | GO:1902495 |
| Domain | Laminin_G | 3.77e-11 | 58 | 153 | 10 | IPR001791 | |
| Domain | ConA-like_dom | TRIM72 FAT4 ZAN FAT3 LAMA4 TRIM39 ADGRV1 THBS1 NELL2 THBS2 EYS THBS4 NBEAL2 CNTNAP4 COL14A1 | 3.59e-10 | 219 | 153 | 15 | IPR013320 |
| Domain | - | 5.64e-09 | 95 | 153 | 10 | 2.60.120.200 | |
| Domain | EGF | FAT4 ZAN FAT3 LAMA4 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 5.50e-07 | 235 | 153 | 12 | SM00181 |
| Domain | Laminin_G_2 | 8.35e-07 | 40 | 153 | 6 | PF02210 | |
| Domain | EGF-like_dom | FAT4 ZAN FAT3 LAMA4 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 1.01e-06 | 249 | 153 | 12 | IPR000742 |
| Domain | TSPN | 1.03e-06 | 23 | 153 | 5 | SM00210 | |
| Domain | EGF_1 | FAT4 ZAN FAT3 LAMA4 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 1.30e-06 | 255 | 153 | 12 | PS00022 |
| Domain | LamG | 1.50e-06 | 44 | 153 | 6 | SM00282 | |
| Domain | EGF-like_CS | FAT4 ZAN FAT3 LAMA4 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 1.66e-06 | 261 | 153 | 12 | IPR013032 |
| Domain | TEA_1 | 2.14e-06 | 4 | 153 | 3 | PS00554 | |
| Domain | TEA_2 | 2.14e-06 | 4 | 153 | 3 | PS51088 | |
| Domain | TEA | 2.14e-06 | 4 | 153 | 3 | PF01285 | |
| Domain | TEA/ATTS_dom | 2.14e-06 | 4 | 153 | 3 | IPR000818 | |
| Domain | TEF_metazoa | 2.14e-06 | 4 | 153 | 3 | IPR016361 | |
| Domain | TEA | 2.14e-06 | 4 | 153 | 3 | SM00426 | |
| Domain | EGF_3 | FAT4 ZAN FAT3 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 3.85e-06 | 235 | 153 | 11 | PS50026 |
| Domain | Sugar/inositol_transpt | 4.07e-06 | 14 | 153 | 4 | IPR003663 | |
| Domain | TSP_3 | 5.33e-06 | 5 | 153 | 3 | PF02412 | |
| Domain | TSP3 | 5.33e-06 | 5 | 153 | 3 | PS51234 | |
| Domain | TSP_CTER | 5.33e-06 | 5 | 153 | 3 | PS51236 | |
| Domain | Thrombospondin_3_rpt | 5.33e-06 | 5 | 153 | 3 | IPR017897 | |
| Domain | TSP_type-3_rpt | 5.33e-06 | 5 | 153 | 3 | IPR028974 | |
| Domain | - | 5.33e-06 | 5 | 153 | 3 | 4.10.1080.10 | |
| Domain | Thrombospondin_C | 5.33e-06 | 5 | 153 | 3 | IPR008859 | |
| Domain | TSP_C | 5.33e-06 | 5 | 153 | 3 | PF05735 | |
| Domain | Thrombospondin_3-like_rpt | 5.33e-06 | 5 | 153 | 3 | IPR003367 | |
| Domain | Sugar_transporter_CS | 5.82e-06 | 32 | 153 | 5 | IPR005829 | |
| Domain | SUGAR_TRANSPORT_2 | 9.48e-06 | 17 | 153 | 4 | PS00217 | |
| Domain | MFS_sugar_transport-like | 1.06e-05 | 36 | 153 | 5 | IPR005828 | |
| Domain | VWFC_1 | 1.06e-05 | 36 | 153 | 5 | PS01208 | |
| Domain | Sugar_tr | 1.06e-05 | 36 | 153 | 5 | PF00083 | |
| Domain | EGF_2 | FAT4 ZAN FAT3 THBS1 NELL2 THBS2 EYS THBS4 TENM1 CNTNAP4 MUC4 | 1.20e-05 | 265 | 153 | 11 | PS01186 |
| Domain | VWFC_2 | 1.39e-05 | 38 | 153 | 5 | PS50184 | |
| Domain | VWC | 1.39e-05 | 38 | 153 | 5 | SM00214 | |
| Domain | LAM_G_DOMAIN | 1.39e-05 | 38 | 153 | 5 | PS50025 | |
| Domain | MFS_dom | SLC2A7 MFSD11 SLC2A2 SLC2A4 SLC2A5 SLC15A2 SLC22A20P SLC29A4 | 1.47e-05 | 134 | 153 | 8 | IPR020846 |
| Domain | VWF_dom | 2.30e-05 | 42 | 153 | 5 | IPR001007 | |
| Domain | SUGAR_TRANSPORT_1 | 4.05e-05 | 24 | 153 | 4 | PS00216 | |
| Domain | EGF_CA | 6.58e-05 | 122 | 153 | 7 | SM00179 | |
| Domain | CATSPERD | 6.67e-05 | 2 | 153 | 2 | PF15020 | |
| Domain | CATSPERD | 6.67e-05 | 2 | 153 | 2 | IPR028751 | |
| Domain | Fru_transpt_5 | 6.67e-05 | 2 | 153 | 2 | IPR002442 | |
| Domain | EGF-like_Ca-bd_dom | 7.29e-05 | 124 | 153 | 7 | IPR001881 | |
| Domain | EGF_CA | 7.51e-05 | 86 | 153 | 6 | PF07645 | |
| Domain | VWC | 7.61e-05 | 28 | 153 | 4 | PF00093 | |
| Domain | K_chnl_volt-dep_ERG | 1.99e-04 | 3 | 153 | 2 | IPR003967 | |
| Domain | Cadherin_CS | 2.77e-04 | 109 | 153 | 6 | IPR020894 | |
| Domain | VWF_type-D | 2.79e-04 | 16 | 153 | 3 | IPR001846 | |
| Domain | VWFD | 2.79e-04 | 16 | 153 | 3 | PS51233 | |
| Domain | VWD | 2.79e-04 | 16 | 153 | 3 | SM00216 | |
| Domain | VWD | 2.79e-04 | 16 | 153 | 3 | PF00094 | |
| Domain | CADHERIN_1 | 3.37e-04 | 113 | 153 | 6 | PS00232 | |
| Domain | Cadherin | 3.37e-04 | 113 | 153 | 6 | PF00028 | |
| Domain | CADHERIN_2 | 3.53e-04 | 114 | 153 | 6 | PS50268 | |
| Domain | - | 3.53e-04 | 114 | 153 | 6 | 2.60.40.60 | |
| Domain | CA | 3.70e-04 | 115 | 153 | 6 | SM00112 | |
| Domain | Cadherin-like | 3.87e-04 | 116 | 153 | 6 | IPR015919 | |
| Domain | Cadherin | 4.25e-04 | 118 | 153 | 6 | IPR002126 | |
| Domain | VWC_out | 4.74e-04 | 19 | 153 | 3 | SM00215 | |
| Domain | EGF | 6.02e-04 | 126 | 153 | 6 | PF00008 | |
| Domain | Sushi | 8.64e-04 | 52 | 153 | 4 | PF00084 | |
| Domain | CCP | 9.96e-04 | 54 | 153 | 4 | SM00032 | |
| Domain | SUSHI | 1.14e-03 | 56 | 153 | 4 | PS50923 | |
| Domain | EGF_Ca-bd_CS | 1.22e-03 | 97 | 153 | 5 | IPR018097 | |
| Domain | Sushi_SCR_CCP_dom | 1.22e-03 | 57 | 153 | 4 | IPR000436 | |
| Domain | EGF_CA | 1.33e-03 | 99 | 153 | 5 | PS01187 | |
| Domain | Growth_fac_rcpt_ | 1.82e-03 | 156 | 153 | 6 | IPR009030 | |
| Domain | MFS | 1.96e-03 | 108 | 153 | 5 | PS50850 | |
| Domain | PAS_9 | 2.87e-03 | 10 | 153 | 2 | PF13426 | |
| Domain | Integrin_alpha | 3.49e-03 | 11 | 153 | 2 | PF00357 | |
| Domain | C8 | 4.17e-03 | 12 | 153 | 2 | PF08742 | |
| Domain | TIL | 4.17e-03 | 12 | 153 | 2 | PF01826 | |
| Domain | Cadherin_C | 4.90e-03 | 42 | 153 | 3 | IPR032455 | |
| Domain | Cadherin_C_2 | 4.90e-03 | 42 | 153 | 3 | PF16492 | |
| Domain | Unchr_dom_Cys-rich | 4.90e-03 | 13 | 153 | 2 | IPR014853 | |
| Domain | C8 | 4.90e-03 | 13 | 153 | 2 | SM00832 | |
| Domain | Dynein_heavy_chain_D4_dom | 5.69e-03 | 14 | 153 | 2 | IPR024317 | |
| Domain | Dynein_HC_stalk | 5.69e-03 | 14 | 153 | 2 | IPR024743 | |
| Domain | Dynein_heavy_dom-2 | 5.69e-03 | 14 | 153 | 2 | IPR013602 | |
| Domain | DHC_N2 | 5.69e-03 | 14 | 153 | 2 | PF08393 | |
| Domain | TIL_dom | 5.69e-03 | 14 | 153 | 2 | IPR002919 | |
| Domain | K_chnl_volt-dep_EAG/ELK/ERG | 5.69e-03 | 14 | 153 | 2 | IPR003938 | |
| Domain | MT | 5.69e-03 | 14 | 153 | 2 | PF12777 | |
| Domain | AAA_8 | 5.69e-03 | 14 | 153 | 2 | PF12780 | |
| Domain | DHC_fam | 6.53e-03 | 15 | 153 | 2 | IPR026983 | |
| Domain | Dynein_heavy | 6.53e-03 | 15 | 153 | 2 | PF03028 | |
| Domain | Dynein_heavy_dom | 6.53e-03 | 15 | 153 | 2 | IPR004273 | |
| Domain | - | 7.12e-03 | 48 | 153 | 3 | 2.60.120.10 | |
| Domain | Post-SET_dom | 7.42e-03 | 16 | 153 | 2 | IPR003616 | |
| Domain | PostSET | 7.42e-03 | 16 | 153 | 2 | SM00508 | |
| Domain | Integrin_alpha_C_CS | 7.42e-03 | 16 | 153 | 2 | IPR018184 | |
| Domain | Sulfatase_CS | 7.42e-03 | 16 | 153 | 2 | IPR024607 | |
| Domain | POST_SET | 7.42e-03 | 16 | 153 | 2 | PS50868 | |
| Pathway | REACTOME_INTESTINAL_ABSORPTION | 5.36e-06 | 5 | 116 | 3 | M27833 | |
| Pathway | REACTOME_RUNX3_REGULATES_YAP1_MEDIATED_TRANSCRIPTION | 1.07e-05 | 6 | 116 | 3 | MM15544 | |
| Pathway | WP_MIR5093P_ALTERATION_OF_YAP1ECM_AXIS | 1.22e-05 | 18 | 116 | 4 | M39421 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | SLC24A5 SLC2A7 SLC38A5 SLC6A15 SLC2A2 SLC2A4 SLC6A3 SLC15A2 SLC29A4 SLC27A4 | 2.66e-05 | 238 | 116 | 10 | MM15076 |
| Pathway | REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION | 2.95e-05 | 8 | 116 | 3 | MM14816 | |
| Pathway | REACTOME_RUNX3_REGULATES_YAP1_MEDIATED_TRANSCRIPTION | 2.95e-05 | 8 | 116 | 3 | M27823 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | SLC24A5 SLC2A7 SLC38A5 SLC6A15 SLC2A2 SLC2A4 SLC6A3 SLC15A2 SLC29A4 SLC27A4 | 3.90e-05 | 249 | 116 | 10 | M5988 |
| Pathway | REACTOME_DIGESTION_AND_ABSORPTION | 4.82e-05 | 25 | 116 | 4 | MM15557 | |
| Pathway | KEGG_ECM_RECEPTOR_INTERACTION | 6.57e-05 | 84 | 116 | 6 | M7098 | |
| Pathway | REACTOME_DIGESTION_AND_ABSORPTION | 7.65e-05 | 28 | 116 | 4 | M27837 | |
| Pathway | REACTOME_DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS | 1.06e-04 | 177 | 116 | 8 | M27476 | |
| Pathway | PID_INTEGRIN1_PATHWAY | 2.07e-04 | 66 | 116 | 5 | M18 | |
| Pathway | REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION | 2.30e-04 | 15 | 116 | 3 | M603 | |
| Pathway | WP_TRANSCRIPTION_COFACTORS_SKI_AND_SKIL_PROTEIN_PARTNERS | 4.05e-04 | 18 | 116 | 3 | M39825 | |
| Pathway | REACTOME_CELLULAR_HEXOSE_TRANSPORT | 4.78e-04 | 19 | 116 | 3 | MM14718 | |
| Pathway | REACTOME_CELLULAR_HEXOSE_TRANSPORT | 6.48e-04 | 21 | 116 | 3 | M27058 | |
| Pubmed | Differential patterns of inhibition of the sugar transporters GLUT2, GLUT5 and GLUT7 by flavonoids. | 8.68e-08 | 3 | 155 | 3 | 29548810 | |
| Pubmed | 8.68e-08 | 3 | 155 | 3 | 25976449 | ||
| Pubmed | 8.68e-08 | 3 | 155 | 3 | 18178577 | ||
| Pubmed | Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. | 8.68e-08 | 3 | 155 | 3 | 12482844 | |
| Pubmed | 3.46e-07 | 4 | 155 | 3 | 8702974 | ||
| Pubmed | Comparative expression analysis of TEADs and their splice variants in mouse embryonic stem cells. | 3.46e-07 | 4 | 155 | 3 | 36516960 | |
| Pubmed | Immunohistochemical localisation of thrombospondin in human megakaryocytes and platelets. | 3.46e-07 | 4 | 155 | 3 | 6338048 | |
| Pubmed | 3.46e-07 | 4 | 155 | 3 | 9889009 | ||
| Pubmed | The TEA domain: a novel, highly conserved DNA-binding motif. | 3.46e-07 | 4 | 155 | 3 | 2070413 | |
| Pubmed | Reassessment of GLUT7 and GLUT9 as Putative Fructose and Glucose Transporters. | 3.46e-07 | 4 | 155 | 3 | 28083649 | |
| Pubmed | Tead transcription factors differentially regulate cortical development. | 3.46e-07 | 4 | 155 | 3 | 32170161 | |
| Pubmed | 3.46e-07 | 4 | 155 | 3 | 9169843 | ||
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 30622267 | ||
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 9671946 | ||
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 21527258 | ||
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 19324877 | ||
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 22677547 | ||
| Pubmed | TEAD mediates YAP-dependent gene induction and growth control. | 8.63e-07 | 5 | 155 | 3 | 18579750 | |
| Pubmed | 8.63e-07 | 5 | 155 | 3 | 10518497 | ||
| Pubmed | 1.72e-06 | 6 | 155 | 3 | 11358867 | ||
| Pubmed | 1.72e-06 | 6 | 155 | 3 | 26572137 | ||
| Pubmed | 1.72e-06 | 6 | 155 | 3 | 25995450 | ||
| Pubmed | 3.00e-06 | 7 | 155 | 3 | 14736747 | ||
| Pubmed | Tead proteins activate the Foxa2 enhancer in the node in cooperation with a second factor. | 3.00e-06 | 7 | 155 | 3 | 16207754 | |
| Pubmed | Thrombospondins 1 and 2 are important for afferent synapse formation and function in the inner ear. | 4.78e-06 | 8 | 155 | 3 | 24460873 | |
| Pubmed | 7.15e-06 | 9 | 155 | 3 | 19956686 | ||
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | FKBP10 TMEM67 FAT4 RBM4 LAMA4 SLC38A5 P4HA3 SLC6A15 ERMP1 CTSA SACM1L THBS1 NELL2 SULF2 XXYLT1 PRPF19 C1QTNF6 GNS | 7.40e-06 | 1201 | 155 | 18 | 35696571 |
| Pubmed | 7.95e-06 | 105 | 155 | 6 | 30280653 | ||
| Pubmed | 1.40e-05 | 11 | 155 | 3 | 17903301 | ||
| Pubmed | 1.57e-05 | 407 | 155 | 10 | 12693553 | ||
| Pubmed | 1.78e-05 | 35 | 155 | 4 | 35858542 | ||
| Pubmed | 1.96e-05 | 332 | 155 | 9 | 37433992 | ||
| Pubmed | Induced thrombospondin expression in the mouse pancreas during pancreatic injury. | 1.97e-05 | 2 | 155 | 2 | 16181801 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 17620335 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 34425286 | ||
| Pubmed | MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. | 1.97e-05 | 2 | 155 | 2 | 18475301 | |
| Pubmed | Modulation of thrombospondin expression during differentiation of embryonal carcinoma cells. | 1.97e-05 | 2 | 155 | 2 | 8126073 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 35968588 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 9694593 | ||
| Pubmed | Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjögren's syndrome. | 1.97e-05 | 2 | 155 | 2 | 24086667 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 32055715 | ||
| Pubmed | Sema4D deficiency enhances glucose tolerance through GLUT2 retention in hepatocytes. | 1.97e-05 | 2 | 155 | 2 | 39334386 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19587264 | ||
| Pubmed | Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. | 1.97e-05 | 2 | 155 | 2 | 10027393 | |
| Pubmed | Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression. | 1.97e-05 | 2 | 155 | 2 | 34958665 | |
| Pubmed | Associations of THBS2 and THBS4 polymorphisms to gastric cancer in a Southeast Chinese population. | 1.97e-05 | 2 | 155 | 2 | 27160021 | |
| Pubmed | An MG53-IRS1-interaction disruptor ameliorates insulin resistance. | 1.97e-05 | 2 | 155 | 2 | 29884820 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 33981184 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 24359226 | ||
| Pubmed | CHD6 regulates the topological arrangement of the CFTR locus. | 1.97e-05 | 2 | 155 | 2 | 25631877 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 30928339 | ||
| Pubmed | Increased cortical expression of two synaptogenic thrombospondins in human brain evolution. | 1.97e-05 | 2 | 155 | 2 | 17182969 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 17143334 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 16934801 | ||
| Pubmed | TEAD1 and TEAD3 Play Redundant Roles in the Regulation of Human Epidermal Proliferation. | 1.97e-05 | 2 | 155 | 2 | 32142794 | |
| Pubmed | Alteration of ocular surface mucins in MUC5AC-DTA transgenic mice. | 1.97e-05 | 2 | 155 | 2 | 19158956 | |
| Pubmed | Interactions of PPAR α and GLUT4 in DOCA/salt-induced renal injury in mice. | 1.97e-05 | 2 | 155 | 2 | 24937386 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 16835241 | ||
| Pubmed | Human cytomegalovirus infection modulates thrombospondins 1 and 2 in primary fetal astrocytes. | 1.97e-05 | 2 | 155 | 2 | 23660684 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 39122122 | ||
| Pubmed | Thrombospondin-1 (TSP1)-null and TSP2-null mice exhibit lower intraocular pressures. | 1.97e-05 | 2 | 155 | 2 | 22930728 | |
| Pubmed | Specificity of MLL1 and TET3 CXXC domains towards naturally occurring cytosine modifications. | 1.97e-05 | 2 | 155 | 2 | 30352306 | |
| Pubmed | Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. | 1.97e-05 | 2 | 155 | 2 | 16148025 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19375584 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 16920711 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 38339060 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 8350346 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 16799633 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 34215797 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 33372257 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 21762961 | ||
| Pubmed | Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. | 1.97e-05 | 2 | 155 | 2 | 22745497 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 12213711 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 29336258 | ||
| Pubmed | Biophysical characterization of the signature domains of thrombospondin-4 and thrombospondin-2. | 1.97e-05 | 2 | 155 | 2 | 16246837 | |
| Pubmed | Thrombospondin expression in aldosterone-producing adenomas. | 1.97e-05 | 2 | 155 | 2 | 12358136 | |
| Pubmed | A second, expressed thrombospondin gene (Thbs2) exists in the mouse genome. | 1.97e-05 | 2 | 155 | 2 | 1712771 | |
| Pubmed | The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. | 1.97e-05 | 2 | 155 | 2 | 9843919 | |
| Pubmed | Effects of testosterone and metformin on glucose metabolism in endometrium. | 1.97e-05 | 2 | 155 | 2 | 19328476 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 24983516 | ||
| Pubmed | Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. | 1.97e-05 | 2 | 155 | 2 | 18594557 | |
| Pubmed | Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. | 1.97e-05 | 2 | 155 | 2 | 15037577 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 15820310 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19856421 | ||
| Pubmed | Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors. | 1.97e-05 | 2 | 155 | 2 | 33759165 | |
| Pubmed | LMTK2-mediated phosphorylation regulates CFTR endocytosis in human airway epithelial cells. | 1.97e-05 | 2 | 155 | 2 | 24727471 | |
| Pubmed | 2.40e-05 | 13 | 155 | 3 | 33984529 | ||
| Pubmed | 3.05e-05 | 14 | 155 | 3 | 36347239 | ||
| Pubmed | Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice. | 3.38e-05 | 41 | 155 | 4 | 23676500 | |
| Pubmed | Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. | 3.92e-05 | 139 | 155 | 6 | 16985003 | |
| Pubmed | Comprehensive proteomic characterization of stem cell-derived extracellular matrices. | 4.29e-05 | 86 | 155 | 5 | 28327460 | |
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 26241338 | ||
| Pubmed | Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. | 5.90e-05 | 3 | 155 | 2 | 18787106 | |
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 12906867 | ||
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 18032585 | ||
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 15121769 | ||
| Pubmed | WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. | 5.90e-05 | 3 | 155 | 2 | 21719793 | |
| Pubmed | Sec16A is critical for both conventional and unconventional secretion of CFTR. | 5.90e-05 | 3 | 155 | 2 | 28067262 | |
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 30939949 | ||
| Pubmed | 5.90e-05 | 3 | 155 | 2 | 29188534 | ||
| GeneFamily | TEA domain transcription factors | 9.22e-07 | 4 | 112 | 3 | 1183 | |
| GeneFamily | Solute carriers | SLC24A5 SLC2A7 SLC25A33 SLC38A5 SLC6A15 SLC2A2 SLC2A4 SLC2A5 SLC6A3 SLC15A2 SLC22A20P SLC29A4 SLC27A4 | 1.02e-06 | 395 | 112 | 13 | 752 |
| GeneFamily | Cadherin related | 1.48e-04 | 17 | 112 | 3 | 24 | |
| GeneFamily | Hyalectan proteoglycans|V-set domain containing|Sushi domain containing|C-type lectin domain containing | 4.28e-04 | 57 | 112 | 4 | 1179 | |
| GeneFamily | Potassium voltage-gated channels | 1.93e-03 | 40 | 112 | 3 | 274 | |
| GeneFamily | Zinc fingers CXXC-type | 2.41e-03 | 12 | 112 | 2 | 136 | |
| GeneFamily | ATP binding cassette subfamily C | 2.84e-03 | 13 | 112 | 2 | 807 | |
| GeneFamily | Cathepsins | 3.79e-03 | 15 | 112 | 2 | 470 | |
| GeneFamily | Dyneins, axonemal | 4.87e-03 | 17 | 112 | 2 | 536 | |
| GeneFamily | Sulfatases | 5.45e-03 | 18 | 112 | 2 | 410 | |
| GeneFamily | CD molecules|Integrin alpha subunits | 5.45e-03 | 18 | 112 | 2 | 1160 | |
| GeneFamily | Immunoglobulin like domain containing|Semaphorins | 6.72e-03 | 20 | 112 | 2 | 736 | |
| GeneFamily | Clustered protocadherins | 7.33e-03 | 64 | 112 | 3 | 20 | |
| GeneFamily | CD molecules|Mucins | 7.40e-03 | 21 | 112 | 2 | 648 | |
| Coexpression | NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER | 1.84e-05 | 94 | 152 | 6 | M18108 | |
| Coexpression | GSE23502_BM_VS_COLON_TUMOR_HDC_KO_MYELOID_DERIVED_SUPPRESSOR_CELL_UP | 2.21e-05 | 199 | 152 | 8 | M8082 | |
| Coexpression | GSE19825_NAIVE_VS_IL2RAHIGH_DAY3_EFF_CD8_TCELL_UP | 2.29e-05 | 200 | 152 | 8 | M4299 | |
| Coexpression | NABA_MATRISOME | NDNF SEMA4D LAMA4 P4HA3 CTSA ITIH2 SEMA3D THBS1 NELL2 THBS2 THBS4 SULF2 COL14A1 C4BPA C1QTNF6 CTSB MUC4 MUC5AC | 2.33e-05 | 1008 | 152 | 18 | MM17056 |
| Coexpression | NABA_MATRISOME | NDNF SEMA4D LAMA4 P4HA3 CTSA ITIH2 SEMA3D THBS1 NELL2 THBS2 EYS THBS4 SULF2 COL14A1 C1QTNF6 CTSB MUC4 MUC5AC | 2.94e-05 | 1026 | 152 | 18 | M5889 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_1000 | FAT4 DDX17 NRCAM FAT3 CFTR WRN PCDHB7 ITGA8 LAMA4 SLC6A15 MSI1 TEAD1 ITGA4 TTC3 CSMD3 SETDB1 SLC15A2 SCN3A ENTPD3 TENM1 CNTNAP4 COL14A1 ASXL2 KIF5C | 2.42e-09 | 818 | 148 | 24 | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_top-relative-expression-ranked_1000 | FAT4 DDX17 SFSWAP NRCAM FAT3 CFTR PCDHB7 ITGA8 LAMA4 SLC38A5 MSI1 TEAD1 ITGA4 RGL1 THBS1 SLC15A2 SCN3A ENTPD3 XXYLT1 CNTNAP4 COL14A1 ASXL2 KIF5C CTSB | 2.42e-09 | 818 | 148 | 24 | gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_top-relative-expression-ranked_500 | NDNF FAT4 FAT3 ITGA8 LAMA4 ABCC9 TEAD1 SETDB1 SEMA3D SLC15A2 SCN3A ENTPD3 CNTNAP4 ASXL2 KIF5C | 1.79e-07 | 408 | 148 | 15 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_500 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_1000 | FAT4 SPEG FAT3 PCDHB7 ITGA8 LAMA4 MSI1 TEAD1 ITGA4 RGL1 SETDB1 SEMA3D THBS4 SLC15A2 SCN3A ENTPD3 CNTNAP4 ASXL2 KIF5C CTSB | 8.54e-07 | 806 | 148 | 20 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_500 | FAT4 FAT3 CFTR WRN ITGA8 CSMD3 SETDB1 SCN3A TENM1 CNTNAP4 COL14A1 ASXL2 KIF5C | 9.59e-06 | 427 | 148 | 13 | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_500 |
| CoexpressionAtlas | kidney_P2_CapMes_Crym_top-relative-expression-ranked_1000 | FKBP10 TMEM67 FAT3 PARP8 CFTR WT1 ITGA8 LAMA4 GBE1 P4HA3 IRS1 MSI1 THBS1 SULF2 FBXO5 KIF5C | 9.77e-06 | 636 | 148 | 16 | gudmap_kidney_P2_CapMes_Crym_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#2_top-relative-expression-ranked_1000 | SPEG FAT3 ITGA8 LAMA4 TEAD1 RGL1 SETDB1 SEMA3D ASXL2 KIF5C CTSB | 1.24e-05 | 312 | 148 | 11 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000_k2 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_1000 | FAT4 DDX17 CENPE WRN ITGA8 LAMA4 SLC38A5 ERMP1 TEAD1 ITGA4 SETDB1 SEMA3D THBS1 THBS2 SLC15A2 ATXN1 COL14A1 ASXL2 | 1.45e-05 | 811 | 148 | 18 | gudmap_developingLowerUrinaryTract_e14.5_ bladder_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#4_top-relative-expression-ranked_1000 | DDX17 SFSWAP FAT3 ITGA8 LAMA4 SLC38A5 TEAD1 RGL1 THBS1 COL14A1 ASXL2 CTSB | 1.70e-05 | 385 | 148 | 12 | gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000_k4 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_k-means-cluster#1_top-relative-expression-ranked_1000 | 2.21e-05 | 217 | 148 | 9 | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_k1_1000 | |
| CoexpressionAtlas | DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_1000 | NDNF POP4 NUP85 NRCAM CENPE PARP8 CFTR WT1 LAMA4 ABCC9 TRIM39 C4orf54 GUF1 THBS2 THBS4 ENTPD3 CNTNAP4 PRPF19 | 2.92e-05 | 855 | 148 | 18 | gudmap_developingKidney_e13.5_podocyte cells_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_100 | 3.08e-05 | 86 | 148 | 6 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_100 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_500_k-means-cluster#5 | 3.37e-05 | 53 | 148 | 5 | Facebase_RNAseq_e9.5_Olfactory Placode_500_K5 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_k-means-cluster#1_top-relative-expression-ranked_500 | 3.61e-05 | 231 | 148 | 9 | gudmap_developingLowerUrinaryTract_e14.5_ bladder_500_k1 | |
| CoexpressionAtlas | DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_100 | 3.74e-05 | 89 | 148 | 6 | gudmap_developingKidney_e13.5_podocyte cells_100 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_top-relative-expression-ranked_1000 | NDNF FAT4 FAT3 WRN PCDHB7 ITGA8 LAMA4 ABCC9 TEAD1 SETDB1 SEMA3D SLC15A2 SCN3A ENTPD3 CNTNAP4 ASXL2 KIF5C | 4.83e-05 | 806 | 148 | 17 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_1000 |
| CoexpressionAtlas | kidney_P3_CapMes_Crym_top-relative-expression-ranked_500 | NDNF TMEM67 FAT3 CFTR WT1 ITGA8 LAMA4 MSI1 FBXO5 SLC15A2 KIF5C | 5.89e-05 | 370 | 148 | 11 | gudmap_kidney_P3_CapMes_Crym_500 |
| CoexpressionAtlas | DevelopingKidney_e13.5_podocyte cells_emap-27773_k-means-cluster#1_top-relative-expression-ranked_100 | 6.16e-05 | 31 | 148 | 4 | gudmap_developingKidney_e13.5_podocyte cells_100_k1 | |
| CoexpressionAtlas | kidney_adult_RenalCapsule_k-means-cluster#1_top-relative-expression-ranked_1000 | 7.00e-05 | 32 | 148 | 4 | gudmap_kidney_adult_RenalCapsule_k1_1000 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#3_top-relative-expression-ranked_1000 | 1.05e-04 | 207 | 148 | 8 | gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000_k3 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_k-means-cluster#5_top-relative-expression-ranked_1000 | DDX17 CENPE WRN ITGA8 LAMA4 TEAD1 SETDB1 SEMA3D THBS1 COL14A1 ASXL2 | 1.10e-04 | 397 | 148 | 11 | gudmap_developingLowerUrinaryTract_e14.5_ bladder_1000_k5 |
| CoexpressionAtlas | DevelopingKidney_e15.5_Cap mesenchyme_emap-27738_top-relative-expression-ranked_1000 | POP4 SPEG FAT3 PARP8 CFTR WT1 ITGA8 TRIM39 MSI1 ADGRV1 MCM10 ITIH2 GUF1 PRPF19 ASXL2 KIF5C | 1.11e-04 | 779 | 148 | 16 | gudmap_developingKidney_e15.5_Cap mesenchyme_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_200 | 1.61e-04 | 165 | 148 | 7 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_200 | |
| CoexpressionAtlas | kidney_e15.5_Podocyte_MafB_top-relative-expression-ranked_1000 | NDNF TMEM67 FAT3 CFTR WT1 ITGA8 GBE1 SLC6A15 TEAD1 SEMA3D NELL2 FBXO5 SLC15A2 GCA COL14A1 RNF139 | 1.83e-04 | 814 | 148 | 16 | gudmap_kidney_e15.5_Podocyte_MafB_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_500 | WRN ITGA8 LAMA4 SLC38A5 TEAD1 SETDB1 SEMA3D THBS1 ATXN1 COL14A1 ASXL2 | 1.84e-04 | 421 | 148 | 11 | gudmap_developingLowerUrinaryTract_e14.5_ bladder_500 |
| CoexpressionAtlas | DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_200 | 1.93e-04 | 170 | 148 | 7 | gudmap_developingKidney_e13.5_podocyte cells_200 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_top-relative-expression-ranked_200 | 1.93e-04 | 170 | 148 | 7 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_200 | |
| CoexpressionAtlas | dev lower uro neuro_e15.5_PelvicGanglion_Sox10_top-relative-expression-ranked_1000 | FAT4 NRCAM FAT3 ITGA8 P4HA3 ABCC9 ITGA4 CSMD3 NELL2 THBS2 SULF2 SCN3A CNTNAP4 COL14A1 KIF5C | 1.94e-04 | 734 | 148 | 15 | gudmap_dev lower uro neuro_e15.5_PelvicGanglion_Sox10_1000 |
| CoexpressionAtlas | kidney_P3_CapMes_Crym_top-relative-expression-ranked_1000 | NDNF TMEM67 FAT3 PARP8 CFTR WT1 ITGA8 LAMA4 IRS1 ERMP1 MSI1 MCM10 FBXO5 SLC15A2 KIF5C | 2.41e-04 | 749 | 148 | 15 | gudmap_kidney_P3_CapMes_Crym_1000 |
| CoexpressionAtlas | facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K2 | NDNF FKBP10 FAT4 TMEM150A EPHA6 ALKBH2 FAT3 LAMA4 P4HA3 CTSA SEMA3D THBS1 THBS2 FBXO24 SULF2 FBXO5 ATXN1 HPS1 SEC16A SLC27A4 | 2.80e-04 | 1208 | 148 | 20 | facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K2 |
| CoexpressionAtlas | dev gonad_e13.5_M_InterstitTestis_Sma_top-relative-expression-ranked_1000 | NDNF TEAD2 CENPE FAT3 ITGA8 P4HA3 ABCC9 IRS1 ITGA4 TEAD3 SEMA3D THBS1 SULF2 COL14A1 QSER1 | 3.55e-04 | 777 | 148 | 15 | gudmap_dev gonad_e13.5_M_InterstitTestis_Sma_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k-means-cluster#5_top-relative-expression-ranked_500 | 4.31e-04 | 194 | 148 | 7 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k5_500 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_1000 | SYNRG ALKBH2 FAT3 PSMB5 SLC38A5 P4HA3 ABCC9 ADGRV1 SLC2A4 SEMA3D THBS1 NELL2 THBS2 ATXN1 NBEAL2 COL14A1 CTSB | 4.47e-04 | 972 | 148 | 17 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_1000 |
| CoexpressionAtlas | kidney_P1_CapMes_Crym_top-relative-expression-ranked_1000 | TMEM67 FAT3 PARP8 CFTR PCDHB7 WT1 ITGA8 GBE1 P4HA3 IRS1 MSI1 THBS1 SULF2 | 5.00e-04 | 633 | 148 | 13 | gudmap_kidney_P1_CapMes_Crym_1000 |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_500 | FAT4 FAT3 PCDHB7 LAMA4 ITGA4 SLC15A2 SCN3A ENTPD3 CNTNAP4 ASXL2 | 5.84e-04 | 407 | 148 | 10 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_500 |
| CoexpressionAtlas | kidney_P0_JuxtaGlom_Ren1_top-relative-expression-ranked_1000 | FAT3 PARP8 CFTR ITGA8 GBE1 P4HA3 ABCC9 ITGA4 SEMA3D THBS1 THBS4 SLC15A2 ATXN1 GCA WDR1 CTSB | 5.90e-04 | 905 | 148 | 16 | gudmap_kidney_P0_JuxtaGlom_Ren1_1000 |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_500 | ALKBH2 PSMB5 SLC38A5 P4HA3 ADGRV1 SLC2A4 SEMA3D NELL2 THBS2 ATXN1 COL14A1 | 6.39e-04 | 488 | 148 | 11 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_500 |
| CoexpressionAtlas | dev lower uro neuro_e15.5_PelvicGanglion_Sox10_k-means-cluster#1_top-relative-expression-ranked_1000 | 7.10e-04 | 211 | 148 | 7 | gudmap_dev lower uro neuro_e15.5_PelvicGanglion_Sox10_k1_1000 | |
| CoexpressionAtlas | kidney_P2_CapMes_Crym_k-means-cluster#3_top-relative-expression-ranked_100 | 7.11e-04 | 6 | 148 | 2 | gudmap_kidney_P2_CapMes_Crym_k3_100 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 ZAN NRCAM FAT3 CFTR ADGRV1 CSMD3 PKHD1L1 TENM1 CNTNAP4 CSMD1 | 5.14e-11 | 184 | 155 | 11 | 2cbed6462fea2622871bb7e49b0df3d984239281 |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 ZAN NRCAM FAT3 CFTR ADGRV1 CSMD3 PKHD1L1 TENM1 CNTNAP4 CSMD1 | 5.14e-11 | 184 | 155 | 11 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 ZAN NRCAM FAT3 CFTR ADGRV1 CSMD3 PKHD1L1 TENM1 CNTNAP4 CSMD1 | 5.14e-11 | 184 | 155 | 11 | 2b19a8c5f823e00812908b23e66bb4e563278aff |
| ToppCell | COVID-19-Fibroblasts-Intermediate_pathological_FB|COVID-19 / group, cell type (main and fine annotations) | 3.19e-08 | 197 | 155 | 9 | f1c8936986123a3151140c374fcd62d6705c530b | |
| ToppCell | COVID-19-lung-Fibroblast|COVID-19 / Disease (COVID-19 only), tissue and cell type | 3.33e-08 | 198 | 155 | 9 | 3ec01a55ade5e1627258cc3cfebb2c3207a4cb43 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 3.33e-08 | 198 | 155 | 9 | 21cf4d81386761d09d0f6829c01c198e5524176d | |
| ToppCell | 10x5'v1-week_12-13-Mesenchymal_osteo-stroma|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 3.48e-08 | 199 | 155 | 9 | d65ee89d5c7e8ed693d58e6a6de09565840e11c5 | |
| ToppCell | 10x5'v1-week_12-13-Mesenchymal_osteo|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 3.48e-08 | 199 | 155 | 9 | bf138cc692df727e087d140c014149ee5da00d9d | |
| ToppCell | facs-Lung-24m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.04e-07 | 162 | 155 | 8 | bf886e22ff2a20353499004b53f25fb9e6574896 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Endothelial-lymphatic_endothelial-LEC2_(MADCAM1+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.06e-07 | 177 | 155 | 8 | 76f5df101c693e5fa61554244d877fc8169ee66f | |
| ToppCell | Mesenchymal_cells-Osteoblasts|Mesenchymal_cells / Lineage and Cell class | 2.66e-07 | 183 | 155 | 8 | d6b52d52fe9a7a6c798947f05420d79fe12e4662 | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_airway_neuro-secretory-Neuroendocrine|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.47e-07 | 196 | 155 | 8 | 95544097577f20ed7f4144bd940471cde0617554 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.83e-07 | 198 | 155 | 8 | d1827e3707b929e3a3562989a0c11537d344e164 | |
| ToppCell | Fetal_29-31_weeks|World / Lineage, Cell type, age group and donor | 5.02e-07 | 199 | 155 | 8 | 5b9d355795dd03a22f0961dfd143425c367a4654 | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_osteo-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.02e-07 | 199 | 155 | 8 | 7b1b3b108d817fb3b50a710c3146b30bcf9c2f6b | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_osteo|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.02e-07 | 199 | 155 | 8 | f2ad641f36c577ff7019e88ad6b73ed7e46d8c74 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 5.21e-07 | 200 | 155 | 8 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.21e-07 | 200 | 155 | 8 | 780d47f8eff630020dfae32218de495a7e9dbad6 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.21e-07 | 200 | 155 | 8 | 28dd127787a57276253548d1f030814b1af64481 | |
| ToppCell | Tracheal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.21e-07 | 200 | 155 | 8 | 3e0041c04e42a47257517dae8707a6454570c256 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 5.21e-07 | 200 | 155 | 8 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| ToppCell | Adult-Immune-enucleated_erythrocyte-D175|Adult / Lineage, Cell type, age group and donor | 1.07e-06 | 152 | 155 | 7 | 530d5427d8617dcb223d807b73abee0ef89285f3 | |
| ToppCell | Ionocyte|World / shred by cell class for nasal brushing | 1.17e-06 | 154 | 155 | 7 | 6b78fb0c96fc7b5e901c39b3424f4aa8d0a6b9cf | |
| ToppCell | LPS-IL1RA+antiTNF-Myeloid-Monocytes,_Macrophages-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.22e-06 | 155 | 155 | 7 | 4559e3011514041b65c17ae4ede29da202bce14c | |
| ToppCell | PND10-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.78e-06 | 164 | 155 | 7 | 4cfc9f92e49f86d3639e018b35b6a60dc62f494a | |
| ToppCell | PND10-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.78e-06 | 164 | 155 | 7 | 7a8e5ef52a8fd2877d59ef0696af8a7af90bbed6 | |
| ToppCell | PND10-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.78e-06 | 164 | 155 | 7 | 5e5bd81414ea2d64f73cdef19a0a78c17bec8c18 | |
| ToppCell | PND10-Endothelial-Endothelial_lymphatic|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.78e-06 | 164 | 155 | 7 | f13b8d9b7f42193f333d9a77571a1dde6bbb48d8 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.01e-06 | 167 | 155 | 7 | 3edb0570e583bb527165bcd8a4c25a042054043b | |
| ToppCell | PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_G2M|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.95e-06 | 177 | 155 | 7 | 3e149bff1f1b393a7abe98984e37981c8296f95d | |
| ToppCell | cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_2-ASMC|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.06e-06 | 178 | 155 | 7 | 8ec2a25dda96c9cc9c2904b6cb18f75a293f4969 | |
| ToppCell | cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_2|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.06e-06 | 178 | 155 | 7 | 6c91331196696e0cf239d105f458e3230659fa38 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_SST_CXCL14|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.30e-06 | 180 | 155 | 7 | b6efdb4d319ef6f87f559acd974e5a71b06a2322 | |
| ToppCell | RA-13._Vascular_Smooth_Muscle|RA / Chamber and Cluster_Paper | 3.68e-06 | 183 | 155 | 7 | 818fd886e0188091310825f9145fa53328f2c979 | |
| ToppCell | NS-critical-d_07-13-Epithelial-Ionocyte|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.68e-06 | 183 | 155 | 7 | ba43bca2b45be1008eebd3f033cecb061fb3a966 | |
| ToppCell | (6)_Endothelial-F_(Lymphatics)|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 3.81e-06 | 184 | 155 | 7 | 03ea613e00b45c81b752c14505a0538d698f551e | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 3.81e-06 | 184 | 155 | 7 | 67164bb6bcae7322cb89b585c7aa10bce35b0ecd | |
| ToppCell | PND07-28-samps-Mesenchymal-Myofibroblast-myofibroblast_-_mature_-_C|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 3.95e-06 | 185 | 155 | 7 | 427176ad9ab8d9511200fb0a132cfd1e835fe35c | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.0.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.95e-06 | 185 | 155 | 7 | 9878392d79734ab5bb977d7f4f5e2e079b9a5353 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.09e-06 | 186 | 155 | 7 | 23b8d51d20b05795a73892d3e20e0f9b6a207820 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.55e-06 | 189 | 155 | 7 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.55e-06 | 189 | 155 | 7 | c734e5693808a0333139e87bd5be2597a9252afe | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.71e-06 | 190 | 155 | 7 | 2e592323085ba9c019d678ac2a784462ab470ed9 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.71e-06 | 190 | 155 | 7 | 445952b70abffadb6ccc1ed4bbf61a88b06b73b3 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.87e-06 | 191 | 155 | 7 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | droplet-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.87e-06 | 191 | 155 | 7 | b51e0f5d1b93f526160c904e9091313a5364f3a7 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.87e-06 | 191 | 155 | 7 | c54c420a94dc749ebc67fc64c5614663f4b9798d | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.87e-06 | 191 | 155 | 7 | cb0aee740b08f7d5fdd2717ecf7429043b277ae7 | |
| ToppCell | 10x3'2.3-week_12-13-Mesenchymal_osteo-stroma-osteoblast_precursor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.87e-06 | 191 | 155 | 7 | 98b907f8fa024cf32e462323b782c5a371327bbd | |
| ToppCell | LPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.04e-06 | 192 | 155 | 7 | 162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.04e-06 | 192 | 155 | 7 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.04e-06 | 192 | 155 | 7 | e0f4e4470a71bfa81d9dcd8594e5f82aafc24f81 | |
| ToppCell | Mesenchymal-matrix_fibroblast_2_cell|World / Lineage, Cell type, age group and donor | 5.04e-06 | 192 | 155 | 7 | a769158c49d2b208c4224d85e7ae68c85cc372ed | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.22e-06 | 193 | 155 | 7 | 9ab47b360bee1d4f1092c2269e58acebe9584021 | |
| ToppCell | TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_NOS-3|TCGA-Stomach / Sample_Type by Project: Shred V9 | 5.40e-06 | 194 | 155 | 7 | 2260cd817a6661e5eb6645b0c6786e18fd58371e | |
| ToppCell | P28-Mesenchymal-myocytic_cell|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.40e-06 | 194 | 155 | 7 | 83e45441c74b7f50b6725876b583229280179dc2 | |
| ToppCell | (6)_Endothelial_cells-(6)_Endothelial-F_(Lymphatics)|(6)_Endothelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 5.40e-06 | 194 | 155 | 7 | 9441202d6fa2ffbef9277d48ae9bc98876c26ec5 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.58e-06 | 195 | 155 | 7 | 3f64e2313ec79a6d5f4013a52722d071172f6c5d | |
| ToppCell | distal-2-Endothelial-Lymphatic|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 5.58e-06 | 195 | 155 | 7 | 8e0f67a67af3bc0b16f48a621f74540f136383b7 | |
| ToppCell | ASK428-Epithelial-Transformed_epithelium|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq | 5.58e-06 | 195 | 155 | 7 | c750602c765a51075ba6ede78e3ba80b62374481 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.58e-06 | 195 | 155 | 7 | 7a5108335353ac160b684650c5da97d6f7f4dbcf | |
| ToppCell | distal-Endothelial-Lymphatic-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 5.58e-06 | 195 | 155 | 7 | f45c1349932ee7eb419cced8a4fdedae3610953f | |
| ToppCell | 10x5'v1-week_17-19-Mesenchymal_osteo-stroma-osteoblast_precursor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.77e-06 | 196 | 155 | 7 | 57df2a57b35be9851ac0b1e5731baa53052511f0 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.77e-06 | 196 | 155 | 7 | 42e9828222a9663525d571633e8a454c30bfa7f8 | |
| ToppCell | distal-Endothelial-Lymphatic|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 5.77e-06 | 196 | 155 | 7 | 3e8a20e1d163dcbd3bbd99fe179d54af02298af0 | |
| ToppCell | facs-Lung-nan|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.77e-06 | 196 | 155 | 7 | b05f77f3990b662682ffeaf0e4c2fb190e0a6e65 | |
| ToppCell | facs-Lung-nan-3m|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.77e-06 | 196 | 155 | 7 | 787c6cd92035e0b1108c2c086c42a229016e476b | |
| ToppCell | 10x5'v1-week_12-13-Mesenchymal_osteo-stroma-early_osteoblast|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.97e-06 | 197 | 155 | 7 | 2ca5ebb708935a90b12b8e98a22ae2d664ed002e | |
| ToppCell | 10x3'2.3-week_12-13-Mesenchymal_osteo-stroma|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.97e-06 | 197 | 155 | 7 | 63b63c6b2f842adb87bc83222ff86796bd9b58f6 | |
| ToppCell | COVID-19-Fibroblasts|COVID-19 / group, cell type (main and fine annotations) | 5.97e-06 | 197 | 155 | 7 | fb847f2277609c31fffcdf49517243ce0684facf | |
| ToppCell | 10x3'2.3-week_12-13-Mesenchymal_osteo|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.97e-06 | 197 | 155 | 7 | fb50903b87498b400c8e16e6a561b6d9458e5d97 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 6.17e-06 | 198 | 155 | 7 | c55608633f66e3d434c5d81324efb07c5120d2c2 | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-osteoblast_precursor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.17e-06 | 198 | 155 | 7 | 9d61483b0decac2fe90045b3474843360b2c49b3 | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-early_osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.17e-06 | 198 | 155 | 7 | 6a539d3b47bd2d4a7ad5c67cad23facffc0ac45f | |
| ToppCell | 367C-Fibroblasts-Fibroblast-B_(Myofibroblast)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 6.17e-06 | 198 | 155 | 7 | 3e5459038fc6ed95f529eb4d1dc5113e16c19012 | |
| ToppCell | (5)_Fibroblasts-(5)_Fibroblast-B_(Myofibroblast)|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4) | 6.17e-06 | 198 | 155 | 7 | 196257c4420ac801ed9fbb444f11718adb7560ae | |
| ToppCell | medial-Endothelial-Lymphatic-2|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.17e-06 | 198 | 155 | 7 | 41983d405215b974044e2e9e6c212b134336a6fe | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 6.17e-06 | 198 | 155 | 7 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | medial-2-Endothelial-Lymphatic|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.17e-06 | 198 | 155 | 7 | e4274584512a72270087a1ab104fab449a2f83bc | |
| ToppCell | Tracheal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.17e-06 | 198 | 155 | 7 | 1e1ea54f0c234f3b6d29064c4881d8a0c0949a75 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo-stroma-osteoblast_precursor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.17e-06 | 198 | 155 | 7 | bc9c9f2c87282b5ef8514773e065d2a6b5dde338 | |
| ToppCell | Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.17e-06 | 198 | 155 | 7 | 22e766df1276c5b14aa0d83f434f47140ebb98ea | |
| ToppCell | medial-Endothelial-Lymphatic|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.17e-06 | 198 | 155 | 7 | 1760fede363544bc0fa2e22fe36aff522abd2525 | |
| ToppCell | Mesenchymal|World / Lineage, Cell type, age group and donor | 6.37e-06 | 199 | 155 | 7 | 4bac110c2b3609f6ee5d0e3275da0824a6240270 | |
| ToppCell | Parenchymal-10x5prime-Endothelial-Endothelia_lymphatic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.37e-06 | 199 | 155 | 7 | 1587d24b19f5bb64a3b6cc1df87c7c472cf41672 | |
| ToppCell | Parenchymal-10x5prime-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.37e-06 | 199 | 155 | 7 | a9c2041e54899cb8ccc026758647f3ae3ca457dd | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 6.37e-06 | 199 | 155 | 7 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 6.37e-06 | 199 | 155 | 7 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | Biopsy_IPF-Mesenchymal-PLIN2+_Fibroblasts|Biopsy_IPF / Sample group, Lineage and Cell type | 6.59e-06 | 200 | 155 | 7 | 2c5626ea8fb4b702d4560117e53edf6cfcf1971e | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo-stroma-early_osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.59e-06 | 200 | 155 | 7 | 16a7c398626b6e82b394eb3ef013bda3a788659d | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | b79628fd1386aa9a3b0e9fa81def0bc100c3c073 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | 50ca6550998e461ef26dd670351060bd940765a8 | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | 9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1 | |
| ToppCell | Bronchial-10x5prime-Endothelial-Endothelia_lymphatic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.59e-06 | 200 | 155 | 7 | c59f262b2b0a7e7dcb2940d1e466f98db6c56625 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.59e-06 | 200 | 155 | 7 | 07d942803360e1a1e8e131d6e31c726dd0db1a0b | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.59e-06 | 200 | 155 | 7 | d0812817ef99608994193787a62d39adeb2070ca | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | a799fc7bb83ad0524362cb5010df949741fb7bf3 | |
| ToppCell | 10x5'v1-week_17-19-Mesenchymal_osteo-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.59e-06 | 200 | 155 | 7 | 3c898e81444b001835c3f1bbc68183078701b135 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | 44a68bacdb3d5bf563bd35952176995850933a81 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.59e-06 | 200 | 155 | 7 | cae972324d1dfea6efeaf6013f265c7c6bb48db4 | |
| Drug | phlorizine | 9.97e-07 | 79 | 152 | 7 | CID000004789 | |
| Drug | ATB-BMPA | 1.81e-06 | 14 | 152 | 4 | CID000122117 | |
| Drug | 4,6-O-ethylidene-D-glucose | 3.26e-06 | 16 | 152 | 4 | CID000114511 | |
| Drug | Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A | 5.23e-06 | 189 | 152 | 9 | 6649_DN | |
| Drug | 0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A | 6.20e-06 | 193 | 152 | 9 | 4289_UP | |
| Drug | Deoxycorticosterone [64-85-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 7.94e-06 | 199 | 152 | 9 | 6476_DN | |
| Drug | Lynestrenol [52-76-6]; Down 200; 14uM; PC3; HG-U133A | 8.27e-06 | 200 | 152 | 9 | 1953_DN | |
| Drug | T 1095 | 8.51e-06 | 20 | 152 | 4 | CID006918410 | |
| Drug | 3-O-methyl-D-glucose | 8.71e-06 | 72 | 152 | 6 | CID000008973 | |
| Drug | 2-deoxy-D-galactopyranose | 9.22e-06 | 110 | 152 | 7 | CID000000040 | |
| Drug | TF-3 | 1.05e-05 | 21 | 152 | 4 | CID006102763 | |
| Drug | Grgds | 1.98e-05 | 83 | 152 | 6 | CID000123811 | |
| Drug | diazoxide | 2.27e-05 | 227 | 152 | 9 | CID000003019 | |
| Drug | chloroquine | TEAD2 SLC2A7 CR1L CTSA SLC2A2 SLC2A4 SLC2A5 KCNH2 COL14A1 CTSB | 2.48e-05 | 288 | 152 | 10 | CID000002719 |
| Drug | Sucrose | 2.75e-05 | 53 | 152 | 5 | ctd:D013395 | |
| Drug | Fenoterol hydrobromide [1944-12-3]; Up 200; 10.4uM; PC3; HT_HG-U133A | 3.15e-05 | 182 | 152 | 8 | 6331_UP | |
| Drug | Fatty Acids | 3.30e-05 | 55 | 152 | 5 | ctd:D005227 | |
| Drug | Glyburide | 4.28e-05 | 58 | 152 | 5 | ctd:D005905 | |
| Drug | LL-Z1271 | 4.43e-05 | 2 | 152 | 2 | CID000099703 | |
| Drug | benzyl-beta-lactoside | 4.43e-05 | 2 | 152 | 2 | CID003462525 | |
| Drug | N-(1-(2,3-dimethoxyphenyl)-4-methyl-3-penten-1-yl)-1-(5-bromofurfuryl)-1-piperidyl-4-amine | 4.43e-05 | 2 | 152 | 2 | ctd:C531033 | |
| Drug | 4-iodobenzoylchloride | 4.43e-05 | 2 | 152 | 2 | CID000074373 | |
| Drug | aspirin chloride | 4.43e-05 | 2 | 152 | 2 | CID000079668 | |
| Drug | bis(alpha-furancarboxylato)oxovanadium(IV) | 4.43e-05 | 2 | 152 | 2 | ctd:C512927 | |
| Drug | phenol-sodium | 4.43e-05 | 2 | 152 | 2 | CID004445035 | |
| Drug | ethylidene glucose | 4.63e-05 | 11 | 152 | 3 | CID000093075 | |
| Drug | carbanilide | 4.63e-05 | 11 | 152 | 3 | CID000007595 | |
| Drug | Danazol [17230-88-5]; Down 200; 11.8uM; PC3; HG-U133A | 4.95e-05 | 194 | 152 | 8 | 1954_DN | |
| Drug | semustine; Down 200; 100uM; PC3; HT_HG-U133A | 4.95e-05 | 194 | 152 | 8 | 7545_DN | |
| Drug | Atovaquone [95233-18-4]; Up 200; 11uM; MCF7; HT_HG-U133A | 4.95e-05 | 194 | 152 | 8 | 4786_UP | |
| Drug | Etofylline [519-37-9]; Up 200; 17.8uM; MCF7; HT_HG-U133A | 5.52e-05 | 197 | 152 | 8 | 5467_UP | |
| Drug | Pivampicillin [33817-20-8]; Up 200; 8.6uM; PC3; HT_HG-U133A | 5.52e-05 | 197 | 152 | 8 | 5046_UP | |
| Drug | Cinoxacin [28657-80-9]; Up 200; 15.2uM; PC3; HT_HG-U133A | 5.92e-05 | 199 | 152 | 8 | 5783_UP | |
| Drug | Ketoprofen [22071-15-4]; Up 200; 15.8uM; MCF7; HT_HG-U133A | 5.92e-05 | 199 | 152 | 8 | 3626_UP | |
| Drug | IAPS-forskolin | 6.14e-05 | 12 | 152 | 3 | CID000163853 | |
| Drug | pioglitazone | 7.04e-05 | 326 | 152 | 10 | CID000004829 | |
| Drug | chromium picolinate | 7.58e-05 | 34 | 152 | 4 | CID000151932 | |
| Drug | Rgds Peptide | 7.90e-05 | 106 | 152 | 6 | CID000107775 | |
| Drug | thiazolidinedione | 9.73e-05 | 274 | 152 | 9 | CID000005437 | |
| Disease | retinal detachment, retinal break | 2.89e-05 | 35 | 149 | 4 | EFO_0005773, EFO_0010698 | |
| Disease | short QT syndrome (implicated_via_orthology) | 7.57e-05 | 3 | 149 | 2 | DOID:0050793 (implicated_via_orthology) | |
| Disease | otitis media (biomarker_via_orthology) | 8.15e-05 | 17 | 149 | 3 | DOID:10754 (biomarker_via_orthology) | |
| Disease | Disorder of eye | 1.06e-04 | 212 | 149 | 7 | C0015397 | |
| Disease | mucinous adenocarcinoma (is_marker_for) | 2.51e-04 | 5 | 149 | 2 | DOID:3030 (is_marker_for) | |
| Disease | interstitial lung disease | 3.74e-04 | 67 | 149 | 4 | EFO_0004244 | |
| Disease | retinitis pigmentosa | 3.75e-04 | 6 | 149 | 2 | MONDO_0019200 | |
| Disease | Cystic kidney | 3.75e-04 | 6 | 149 | 2 | C0022679 | |
| Disease | schizophrenia (implicated_via_orthology) | 3.96e-04 | 68 | 149 | 4 | DOID:5419 (implicated_via_orthology) | |
| Disease | biliary tract benign neoplasm (is_marker_for) | 5.23e-04 | 7 | 149 | 2 | DOID:0050625 (is_marker_for) | |
| Disease | Albinism, Oculocutaneous | 5.23e-04 | 7 | 149 | 2 | C0078918 | |
| Disease | fatty liver disease (biomarker_via_orthology) | 6.16e-04 | 33 | 149 | 3 | DOID:9452 (biomarker_via_orthology) | |
| Disease | cesarean section, anxiety | 6.95e-04 | 8 | 149 | 2 | EFO_0005230, EFO_0009636 | |
| Disease | leukocyte immunoglobulin-like receptor subfamily B member 4 measurement | 6.95e-04 | 8 | 149 | 2 | EFO_0801768 | |
| Disease | common bile duct neoplasm (is_marker_for) | 6.95e-04 | 8 | 149 | 2 | DOID:4608 (is_marker_for) | |
| Disease | parasitemia measurement | 8.64e-04 | 37 | 149 | 3 | EFO_0005528 | |
| Disease | neurodegenerative disease (implicated_via_orthology) | 8.67e-04 | 145 | 149 | 5 | DOID:1289 (implicated_via_orthology) | |
| Disease | Colorectal Carcinoma | DNAH3 ZNF560 NRCAM PARP8 CFTR WRN CSMD3 CPO TENM1 DIP2C UQCRC2 | 9.10e-04 | 702 | 149 | 11 | C0009402 |
| Disease | long QT syndrome (implicated_via_orthology) | 1.11e-03 | 10 | 149 | 2 | DOID:2843 (implicated_via_orthology) | |
| Disease | uric acid measurement | DNAH3 FAT4 FAT3 LMTK2 ADGRV1 SLC2A2 SLC15A2 DIP2C ASXL2 WDR1 | 1.11e-03 | 610 | 149 | 10 | EFO_0004761 |
| Disease | Malignant neoplasm of breast | CATSPERE NRCAM WT1 MSI1 TTC3 SLC2A2 SLC2A5 SLC6A3 RGL1 THBS1 SULF2 N4BP2 TENM1 DIP2C | 1.12e-03 | 1074 | 149 | 14 | C0006142 |
| Disease | eye color | 1.14e-03 | 90 | 149 | 4 | EFO_0003949 | |
| Disease | ovarian carcinoma | 1.27e-03 | 321 | 149 | 7 | EFO_0001075 | |
| Disease | Atrial Fibrillation | 1.34e-03 | 160 | 149 | 5 | C0004238 | |
| Disease | Shortened QT interval | 1.35e-03 | 11 | 149 | 2 | C0151879 | |
| Disease | Cystic Kidney Diseases | 1.35e-03 | 11 | 149 | 2 | C1691228 | |
| Disease | heart rate variability measurement, response to antipsychotic drug | 1.63e-03 | 46 | 149 | 3 | EFO_0008003, GO_0097332 | |
| Disease | response to angiotensin-converting enzyme inhibitor, Cough | 1.63e-03 | 46 | 149 | 3 | EFO_0005325, HP_0012735 | |
| Disease | aspartate aminotransferase measurement | DVL2 ARHGAP9 LCT SLC2A2 SLC2A4 STN1 RGL1 SETDB1 ATXN1 DSTYK SAMM50 CSMD1 | 2.19e-03 | 904 | 149 | 12 | EFO_0004736 |
| Disease | gastric ulcer (implicated_via_orthology) | 2.21e-03 | 14 | 149 | 2 | DOID:10808 (implicated_via_orthology) | |
| Disease | Streptozotocin Diabetes | 2.23e-03 | 108 | 149 | 4 | C0038433 | |
| Disease | Diabetes Mellitus, Experimental | 2.23e-03 | 108 | 149 | 4 | C0011853 | |
| Disease | Alloxan Diabetes | 2.23e-03 | 108 | 149 | 4 | C0002152 | |
| Disease | Ciliopathies | 2.38e-03 | 110 | 149 | 4 | C4277690 | |
| Disease | pancreatic cancer (is_implicated_in) | 2.54e-03 | 112 | 149 | 4 | DOID:1793 (is_implicated_in) | |
| Disease | pneumonia, COVID-19 | 2.63e-03 | 113 | 149 | 4 | EFO_0003106, MONDO_0100096 | |
| Disease | leukemia | 2.73e-03 | 55 | 149 | 3 | C0023418 | |
| Disease | Drug habituation | 2.80e-03 | 115 | 149 | 4 | C0013170 | |
| Disease | Drug abuse | 2.80e-03 | 115 | 149 | 4 | C0013146 | |
| Disease | Prescription Drug Abuse | 2.80e-03 | 115 | 149 | 4 | C4316881 | |
| Disease | Substance-Related Disorders | 2.80e-03 | 115 | 149 | 4 | C0236969 | |
| Disease | Drug Use Disorders | 2.80e-03 | 115 | 149 | 4 | C0013222 | |
| Disease | Drug Dependence | 2.80e-03 | 115 | 149 | 4 | C1510472 | |
| Disease | Substance Dependence | 2.80e-03 | 115 | 149 | 4 | C0038580 | |
| Disease | Substance Use Disorders | 2.80e-03 | 115 | 149 | 4 | C0038586 | |
| Disease | Organic Mental Disorders, Substance-Induced | 2.80e-03 | 115 | 149 | 4 | C0029231 | |
| Disease | Substance abuse problem | 2.89e-03 | 116 | 149 | 4 | C0740858 | |
| Disease | Diabetic Angiopathies | 2.90e-03 | 16 | 149 | 2 | C0011875 | |
| Disease | Microangiopathy, Diabetic | 2.90e-03 | 16 | 149 | 2 | C0025945 | |
| Disease | amygdala volume change measurement | 2.90e-03 | 16 | 149 | 2 | EFO_0021490 | |
| Disease | diabetic retinopathy (implicated_via_orthology) | 2.90e-03 | 16 | 149 | 2 | DOID:8947 (implicated_via_orthology) | |
| Disease | Lipidemias | 3.28e-03 | 17 | 149 | 2 | C1706412 | |
| Disease | Hyperlipidemia | 3.28e-03 | 17 | 149 | 2 | C0020473 | |
| Disease | cortical surface area measurement | SEMA4D ZAN FAT3 SLC6A15 ADGRV1 DNAH7 STN1 SACM1L TG SEMA3D THBS1 SULF2 DSTYK QSER1 WDR1 | 3.40e-03 | 1345 | 149 | 15 | EFO_0010736 |
| Disease | Insulin Resistance | 3.50e-03 | 60 | 149 | 3 | C0021655 | |
| Disease | Insulin Sensitivity | 3.50e-03 | 60 | 149 | 3 | C0920563 | |
| Disease | pancreatic ductal carcinoma (is_marker_for) | 3.67e-03 | 61 | 149 | 3 | DOID:3587 (is_marker_for) | |
| Disease | cystic fibrosis (is_marker_for) | 3.84e-03 | 62 | 149 | 3 | DOID:1485 (is_marker_for) | |
| Disease | cutaneous melanoma, hair color | 3.84e-03 | 62 | 149 | 3 | EFO_0000389, EFO_0003924 | |
| Disease | melanoma | 3.88e-03 | 126 | 149 | 4 | EFO_0000756 | |
| Disease | Sarcomatoid Renal Cell Carcinoma | 4.10e-03 | 128 | 149 | 4 | C1266043 | |
| Disease | Chromophobe Renal Cell Carcinoma | 4.10e-03 | 128 | 149 | 4 | C1266042 | |
| Disease | Collecting Duct Carcinoma of the Kidney | 4.10e-03 | 128 | 149 | 4 | C1266044 | |
| Disease | Papillary Renal Cell Carcinoma | 4.10e-03 | 128 | 149 | 4 | C1306837 | |
| Disease | Renal Cell Carcinoma | 4.10e-03 | 128 | 149 | 4 | C0007134 | |
| Disease | cholangiocarcinoma (is_marker_for) | 4.20e-03 | 64 | 149 | 3 | DOID:4947 (is_marker_for) | |
| Disease | cortical thickness | SEMA4D FAT3 ABCC9 SLC6A15 ADGRV1 STN1 SACM1L TG THBS1 NELL2 SULF2 KMT2A QSER1 | 4.32e-03 | 1113 | 149 | 13 | EFO_0004840 |
| Disease | joint damage measurement | 4.98e-03 | 68 | 149 | 3 | EFO_0005413 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| KQATYGDAGLTYTFS | 111 | Q6NS38 | |
| HSGEENFYAYGFSVT | 186 | P04003 | |
| EGSSYFYGTFSELQN | 621 | P13569 | |
| GAFSVYSDFLLYKSG | 251 | P07858 | |
| GFQATFYENGYTSDG | 436 | Q86XM0 | |
| FIFLSTSGQTYFLYA | 541 | Q5SY80 | |
| TSGQTYFLYALDDGT | 546 | Q5SY80 | |
| FSISYEGFNITFSEY | 1026 | Q96PZ7 | |
| DFTTSGFFVLSYHAY | 2376 | Q7Z407 | |
| SLFGDTYETQVIAYG | 201 | P46952 | |
| GYTFVAEAFTGDTYV | 1061 | Q8N7X0 | |
| GDSVYTYFSAVAGQD | 51 | P28676 | |
| YYSITGTNNHGTFSI | 1351 | Q6V0I7 | |
| HGTYGYVTADFISQS | 4426 | Q8WXG9 | |
| SAYFGSGSSVIYNFQ | 1001 | Q9C0A0 | |
| LASAGFYYVGNSDDV | 276 | Q13489 | |
| NTGKADQTYYVAGFS | 1026 | O60706 | |
| TFQFIGSSQYSGTYA | 126 | P54253 | |
| SYTFELRDSGTYGFV | 306 | Q8IVL8 | |
| ITYSIVSASAFGSYF | 596 | Q9H251 | |
| VSASAFGSYFDISLY | 601 | Q9H251 | |
| TFSEQCYYVFGDLSG | 496 | O14641 | |
| GSFSIDFLGGFTSYY | 166 | Q7Z2K6 | |
| DFLGGFTSYYDNITN | 171 | Q7Z2K6 | |
| AEAFSSSGMEYFNTY | 296 | Q8TBG4 | |
| EQFFESYYGQSSGLS | 371 | Q76L83 | |
| AGFYYTASALNLSGS | 371 | O75355 | |
| VYDFLYGNKSISFTG | 81 | Q8NH16 | |
| AAAAAVTAASTSYYG | 291 | Q9BWF3 | |
| FNASYSDSGLFGIYT | 326 | P22695 | |
| AATNSYLGYFGDAKS | 1406 | Q2KHR3 | |
| GDNDFTYISIFLSTY | 86 | Q9NZL6 | |
| TGVLYALSSFDYEQF | 511 | O60330 | |
| SLSSGYASFDYEDAG | 531 | Q8N442 | |
| YLSSVEAGGATAFIY | 466 | Q7Z4N8 | |
| TDGSRSYALFLYQSG | 4476 | Q99102 | |
| DFRYSDSTFTFTYVG | 31 | Q8N3A8 | |
| TSTAALVFYYVTGFF | 181 | Q9NSA2 | |
| FVFGGYTGDIYSNSN | 131 | Q8N653 | |
| TDAFGYTSFLAYSRI | 2421 | Q5T1H1 | |
| FSLESQTTIGYGFRY | 121 | P78508 | |
| YFEGERNTVYSSSGV | 341 | Q99435 | |
| STYFGKLGFYFQSED | 756 | P19823 | |
| FYFYAQTSAGSGSQI | 1026 | Q92823 | |
| ATLSAAFGSAFQYGY | 26 | Q6PXP3 | |
| LFGGYDSFRSYNSSV | 26 | Q969R5 | |
| SGINAVFYYSTSIFE | 301 | P14672 | |
| VFYYSTSIFETAGVG | 306 | P14672 | |
| YFTFSSLTSVGFGNV | 616 | Q12809 | |
| ALYFTFSSLTSVGFG | 466 | Q9H252 | |
| YYAQSSLDLFLGGES | 326 | Q9BW27 | |
| LYTAGTFSLNFYGSD | 156 | Q8NGZ2 | |
| VGGFLSSFIETYSVY | 151 | Q8NGI9 | |
| GFTDSYSQKAFCGIY | 166 | Q8TEB1 | |
| FSGINGIFYYSTSIF | 316 | P11168 | |
| GIFYYSTSIFQTAGI | 321 | P11168 | |
| INGTYDFFGFNHYTT | 1671 | P09848 | |
| FSYKGNDVEYFISSS | 126 | Q8TB73 | |
| TFTAGSQGSYRDSAY | 1091 | Q8IWU2 | |
| YGGVSSASYAASIAA | 461 | Q7L590 | |
| YLTFDGQSYSFNGDC | 911 | P98088 | |
| ETFGSSGTLAAYYRL | 481 | Q96KJ4 | |
| EGINSEITYSFYRTG | 271 | Q9Y5G0 | |
| YVNIEFGSDQSGYLS | 896 | P35568 | |
| TAYTGLELTFFSGVY | 246 | O43934 | |
| GFQATTYASRSYTGL | 221 | O43347 | |
| FTGKYDNSVDVYAFG | 821 | Q6XUX3 | |
| YLGYSVAAGEFTGDS | 266 | P53708 | |
| YFVTTLGYNFSSEAG | 901 | Q9UHC9 | |
| GVGFSYSDDKFYATN | 131 | P10619 | |
| TSIAFSENGYYLATA | 396 | Q9UMS4 | |
| TGSNGEIAYAFSYAT | 271 | Q9Y5E2 | |
| FYGTGFGVYLSSAAT | 251 | O76099 | |
| IFEKFSSYDTGYTSQ | 146 | Q7Z6W7 | |
| YASFGYQITSFFAAS | 246 | Q04446 | |
| YQITSFFAASSRYGT | 251 | Q04446 | |
| YNGTLLDGTSFDTSY | 181 | Q96AY3 | |
| FDTSYSKGGTYDTYV | 191 | Q96AY3 | |
| AIYSNDFDTYITFSG | 256 | Q9BXI9 | |
| ISGFYFTQSFLTGVS | 3966 | Q8TD57 | |
| ADFYRTVSSFGVVYD | 1456 | Q8TD26 | |
| LYEDSGYSSFSLQSG | 141 | Q9UKT4 | |
| GYSIFAIGVADADYS | 1161 | Q05707 | |
| DGSSFVYYPSGNVAV | 381 | Q8ND61 | |
| NGDFTSISREYFHYG | 166 | Q2VPA4 | |
| IASYDYHQGSGTFLF | 166 | Q6V1X1 | |
| YFESPFTISDGIYGS | 181 | P00414 | |
| SSGVVAYLGAFTSTY | 2911 | Q8WXX0 | |
| TATDADIGSNGEFYY | 181 | Q8TDW7 | |
| YFQTLSTESSIYFGA | 3946 | Q8TDW7 | |
| NASGYFTIYGDESLQ | 1381 | Q9Y2E4 | |
| SSTLYVTDQGGVYFE | 311 | O75426 | |
| IFYTSDNGYHTGQFS | 321 | P15586 | |
| YIYNGRADGISSTFS | 401 | P13612 | |
| YYNFTRTVISSGGEE | 2681 | Q03164 | |
| LSYFSYGNQTIGSIS | 46 | Q3LHN0 | |
| GAAAYGTSSYTAQEY | 641 | Q92841 | |
| GYTTLLFQEGDFYCS | 596 | Q92902 | |
| YSFVDYASFGGSDET | 401 | D6RIA3 | |
| FQFSYGTKETSYGLS | 161 | Q9Y512 | |
| ASGAATAYFSSFSAY | 176 | A6NK97 | |
| TRYFSVFYLSINAGS | 181 | Q16348 | |
| LNVDGFYFSTTYDLT | 126 | Q9NTJ5 | |
| TIFAYGQTASGKTYT | 81 | Q02224 | |
| IFSASNYYEVGSNRG | 506 | O14830 | |
| RAASYFFDGSGYAVV | 1046 | Q16363 | |
| LLFYYASGSDVFSIS | 1271 | Q16363 | |
| SGSFGFTEYQYLGSC | 46 | Q07869 | |
| TGYSGYSQKFEFETG | 521 | Q9UF33 | |
| KSIFYNDEGYSFSSV | 916 | Q5HYA8 | |
| LHIDFYGAYNTSAFG | 101 | Q8WU17 | |
| SGNYFVTMFDDYSAT | 516 | Q9H2J7 | |
| AEDGSYNAVGFTYGS | 141 | Q12872 | |
| AFYSYGVDDSTGVIN | 71 | Q9H668 | |
| FLDYEAGTLSFYNVT | 461 | Q9HCM9 | |
| GYNYGSFENVSGSTD | 356 | Q8NBJ9 | |
| GYVSNGSVYFDTAKF | 261 | P49589 | |
| FYGTFSYEFGAVSSD | 221 | Q86TG1 | |
| TYSGAVFYTGVNDDG | 161 | Q969N4 | |
| YAAFGSYSSNFAVST | 876 | Q9UMZ2 | |
| EGYNGTIFAYGQTSS | 76 | O60282 | |
| GLTATFGYLTFYSSV | 306 | Q8WUX1 | |
| TNYDEFNGYAGSLFS | 76 | O94906 | |
| TLIAAFGSSFQYGYN | 21 | P22732 | |
| LYSFFTSSGSGFEAF | 631 | Q6ZNJ1 | |
| VETDGFISYIYGSKF | 186 | O95707 | |
| YNFTYNSEGDLGAIT | 1566 | Q9UKZ4 | |
| ISSGGFYGVSSQYES | 321 | Q15562 | |
| FLEFTGSIVYSYDAS | 46 | Q14191 | |
| FSVADGYSENNVFYG | 516 | O75083 | |
| GRNPNYGYTSFDTFS | 356 | Q9NY46 | |
| GELYSGTSYNFLGSE | 171 | Q92854 | |
| FYRGLTASYAGISET | 186 | Q9BSK2 | |
| FFDDGYASYVTQSEL | 296 | Q15047 | |
| TDEYLYSGTASDFLG | 196 | O95025 | |
| AGFIFGYQDSSSFYV | 796 | P35443 | |
| YFSQSYGAFTGESLA | 361 | O60296 | |
| DYAGFVFGYQSSSRF | 1021 | P07996 | |
| GDFAYGTYRSNFSSG | 1401 | O15027 | |
| VASDLYGSAFSLYRG | 251 | Q15772 | |
| GFTDKLFYIYTSGTT | 236 | Q6P1M0 | |
| PGAFYGVSSQYSSAD | 311 | Q99594 | |
| TSFSSGFVVFSFLGY | 356 | Q01959 | |
| NQGYSTVTFDGTPSY | 146 | P19544 | |
| NSFGLDATGTFFSRY | 911 | P53804 | |
| QSRTDSGIFYEDSGY | 261 | Q71RS6 | |
| SGIFYEDSGYSQLSI | 266 | Q71RS6 | |
| YAFTYTGADGQQVSL | 31 | Q9BRR9 | |
| YLSFGDGVLSFYDAS | 416 | Q6ZMU5 | |
| ITNISYTSTFYGFKE | 2906 | Q86WI1 | |
| FSSFKYSGNAVVESY | 1226 | O43151 | |
| QLGTYVFTGESYSRS | 676 | Q8IZJ1 | |
| DESYLSFGFTYFGNR | 111 | Q49AG3 | |
| ASTDDAGIQYSVFYF | 596 | Q6P2C0 | |
| VAFGCTVQQSSFYGY | 176 | Q7RTT9 | |
| DDDYAGFVFGYQSSS | 1021 | P35442 | |
| DAGAFYGVTSQYESS | 301 | P28347 | |
| YYVDSEGNRISGATF | 171 | P28074 | |
| SGATFSVGSGSVYAY | 181 | P28074 | |
| ALSRLYFGTSGYFSQ | 371 | P01266 | |
| YFGTSGYFSQHDLFS | 376 | P01266 | |
| TFAVYLNSTGYRTAF | 126 | Q8IWU5 | |
| GGFLYVTSTYQSLQD | 1031 | O95405 | |
| SFEGTDYGKAFIYQS | 291 | Q96MR9 | |
| HFSAGLGTYYSDSIF | 191 | Q8NBI6 | |
| LGTYYSDSIFFLSVA | 196 | Q8NBI6 | |
| SNGIYYQLGSSFLTE | 2656 | Q9Y493 | |
| SGVILSTDDYFYING | 466 | Q86UW6 | |
| FYLYDLGSTHGTFLN | 231 | Q9BWU0 |